Immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4), have indicated remarkable improvement in the prognosis for the treatment of dozens of cancers (9). Here, PDCD1 is linked to cancer.